摘要
目的探讨罗格列酮(RGZ)对肺成纤维HELF细胞增殖的影响,并探讨p38丝裂原活化蛋白激酶(p38MAPK)通路在其中的作用。方法HELF细胞培养于DMEM培养液中,实验分为:对照组、TGF-β1组、低剂量RGZ(LD-RGZ)组和高剂量RGZ(HD-RGZ)组。CCK-8检测细胞增殖。流式细胞仪检测细胞周期。Western blot检测蛋白表达。结果24 h、48 h和72 h时HD-RGZ组细胞增殖OD450值显著低于LD-RGZ组(P<0.05),LD-RGZ组又显著低于TGF-β1组(P<0.05)。对照组、TGF-β1组、LD-RGZ组和HD-RGZ组G1期细胞分别占细胞周期的(91.23±6.32)%、(70.35±4.14)%、(76.12±4.38)%和(82.35±5.16)%,各组间存在显著差异(P<0.05)。其中,HD-RGZ组G1期细胞比例显著高于LD-RGZ组(P<0.05),LD-RGZ组又显著高于TGF-β1组(P<0.05)。HD-RGZ组Col I、Col III和P-p38MAPK蛋白显著低于LD-RGZ组(P<0.01),LD-RGZ组又显著低于TGF-β1组(P<0.01)。结论罗格列酮抑制p38MAPK通路,进一步抑制肺成纤维细胞增殖以及胶原的合成。
Objective To observe the effects of rosiglitazone(RGZ)on the proliferation of HELF cells(human embryonic lung fibroblast)and p38/MAPK signaling.Methods HELF cells were cultured in DMEM medium.The cells were divided into a control group,TGF-β1 group,low dose RGz(LD-RGZ)group,and high dose RGZ(HD-RGZ)group.CCK-8 was used to detect cell proliferation,and the cell cycle was detected by flow cytometry.Western blot was used to detect protein expression.Results At 24,48,and 72 h,the OD450 values in the HD-RGZ group were significantly lower than those in the LD-RGZ group(P<0.05),and those in the LD-RGZ group were significantly lower than the values in the TGF-β1 group(P<0.05).The proportion of G1 phase cells in the control,TGF-β,LD-RGZ,and HD-RGZ groups was(91.23±6.32)%,(70.35±4.14)%,(76.12±4.38)%,and(82.35±5.16)%,respectively.There was a significant difference among the groups(P<0.05).The percentage of G1 phase cells in the HD-RGZ group was significantly higher than that in the LD-RGZ group(P<0.05),and the proportion in the LD-RGZ group was significantly higher than that in the TGF-β1 group(P<0.05).The protein expression of Col I,Col III,and phospho-p38/MAPK in the HD-RGZ group was significantly lower than that in the LD-RGZ group(P<0.01),and the levels in the LD-RGZ group were significantly lower than those in the TGF-β1 group(P<0.01).Conclusions RGZ can inhibit the p38/MAPK pathway to impair the proliferation and collagen synthesis of pulmonary fibroblasts.
作者
史方海
陈忠仁
SHI Fanghai;CHEN Zhongren(Department of Respiratory Medicine,Haikou People’s Hospital,Haikou 570208)
出处
《中国比较医学杂志》
CAS
北大核心
2021年第2期93-97,共5页
Chinese Journal of Comparative Medicine
基金
海南省自然科学基金面上项目(818MS136)。
